Fragmentation in US health care delivery streams and shortcomings in formal quality measures mean that transparency could be more useful to policymakers and regulators than patients.
AMA J Ethics. 2022;24(11):E1075-1082. doi:
10.1001/amajethics.2022.1075.
Sarosh Nagar, Leah Z. Rand, PhD, and Aaron S. Kesselheim, MD, JD, MPH
This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation of Economic Co-operation and Development member nations.
AMA J Ethics. 2022;24(11):E1083-1090. doi:
10.1001/amajethics.2022.1083.
Cultural failure to recognize tacit knowledge explains why credential-based knowledge has higher status and prioritizes clinicians who do not care on an hour-to-hour basis for most of our country’s elders.
AMA J Ethics. 2022;24(9):E883-889. doi:
10.1001/amajethics.2022.883.
Some commentators say comparative trials of FDA-approved drugs are overburdened by current Common Rule regulations and that researchers should not be required to obtain explicit consent for participation in the most innocuous of these trials.
Mollie Gordon, MD, Rebecca Chen, MD, John Coverdale, MD, MEd, Mike Schiller, CRMP, Hanni Stoklosa, MD, MPH, and Phuong Nguyen, PhD
Little attention has been given to roles played by human trafficking in health care organizations’ supply chains of key equipment, such as hand sanitizers and gloves.
AMA J Ethics. 2024;26(4):E348-356. doi:
10.1001/amajethics.2024.348.